Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP

Journal of Investigative Dermatology

Volumn 130, Issue 3, 2010, Pages 826-840

  Braun, Frank K ^a   Hirsch, Burkhard ^a   Al Yacoub, Nadya ^a   Dürkop, Horst ^a   Assaf, Chalid ^a   Kadin, Marshall E ^b   Sterry, Wolfram ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 LIGAND; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; LIGATION; PRIORITY JOURNAL; SKIN LYMPHOMA; STIMULATION; UPREGULATION;

ANTIGENS, CD30; ANTIGENS, CD95; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NF-KAPPA B; RECEPTOR CROSS-TALK; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA INTERFERENCE; SKIN NEOPLASMS; UP-REGULATION;

EID: 76649114985     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.299     Document Type: Article

References (58)

1. Al-Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPAR delta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940-1949
2. Ashkenazi A (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19:325-331
3. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R et al. (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261-266
4. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP et al. (2008) A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30(+) hematologic malignancies. Blood 111:1848-1854
5. Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A et al. (2005) The fully human anti-CD30 antibody 5F11 activates NF-\{kappa\}B and sensitizes lymphoma cells to bortezomib-induced apoptosi. Blood 106:1839-1842
6. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H et al. (2007) Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 127:2425-2437
7. Contassot E, Kerl K, Roques S, Shane R, Gaide O, Dupuis M et al. (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780-4787
8. Day TW, Najafi F, Wu CH, Safa AR (2006) Cellular FLICE-like inhibitory protein (c-FLIP): a novel target for Taxol-induced apoptosis. Biochem Pharmacol 71:1551-1561
9. Dummer R (2006) Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 33:S33-6
10. Durkop H, Hirsch B, Hahn C, Stein H (2006) cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3. J Mol Med 84:132-141
11. Dutton A, Young LS, Murray PG (2006) The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 10:27-35
12. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 22:9131-9141
13. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF (2007) Overcoming apoptosis deficiency of melanoma\-hope for new therapeutic approaches. Drug Resist Updat 10:218-234
14. Fanale MA, Younes A (2007) Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-350
15. Fulda S (2008) Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 8:132-140
16. Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J (2005) Apo2L/ TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 579:6217-6222
17. Gomez-Santos C, Francisco R, Gimenez-Xavier P, Ambrosio S (2007) Dopamine induces TNFalpha and TNF-R1 expression in SH-SY5Y human neuroblastoma cells. Neuroreport 18:1725-1728
18. Greisser J, Doebbeling U, Roos M, Mueller B, Schmid M, Burg G et al. (2005) Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 14:380-385
19. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N et al. (1996) CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149:469-481
20. Guitart J (2006) Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Semin Oncol 33(Suppl 3):S17-20
21. Gupta S, Bi R, Gollapudi S (2005) Central memory and effector memory subsets of human CD4(+) and CD8(+). Ann N Y Acad Sci 1050: 108-114
22. Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R et al. (2008) CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 172: 510-520
23. Hubinger G, Schneider C, Stohr D, Ruff H, Kirchner D, Schwanen C et al. (2004) CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells. Exp Hematol 32:382-389
24. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD et al. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-ediated activation-induced cell death. Nature 434:88-93
25. Kadin ME (2006) Pathobiology of CD30+ cutaneous T-cell lymphomas. J Cutan Pathol 33(Suppl 1):10-17
26. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
27. Karst AM, Li G (2007) BH3-only proteins in tumorigenesis and malignant melanoma. Cell Mol Life Sci 64:318-330 (Pubitemid 46440203)
28. Kennedy MK, Willis CR, Armitage RJ (2006) Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118:143-152
29. Kruyt FAE (2008) TRAIL and cancer therapy. Cancer Lett 263:14-25
30. Lavrik IN, Golks A, Krammer PH (2005) Death receptor signaling. J Cell Sci 118:265-267
31. Levi E, Pfeifer WM, Kadin ME (2001) CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood 98:1630-1632
32. Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R et al. (2000) Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol 115:1034-1040
33. Li HL, Zhu H, Xu CJ, Yuan JY (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501
34. Li-Weber M, Krammer PH (2003) Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15:145-157
35. Los M, Stroh C, Janicke RU, Engels IH, Schulze-Osthoff K (2001) Caspases: more than just killers? Trends Immunol 22:31-34
36. Mathas S, Lietz A, Anagnostopoulos L, Hummel F, Wiesner B, Janz M et al. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199:1041-1052
37. Mathiasen IS, Hansen CM, Foghsgaard L, Jaattela M (2001) Sensitization to TNF-induced apoptosis by 1,25-dihydroxy vitamin D(3) involves up-regulation of the TNF receptor 1 and cathepsin B. Int J Cancer 15:224-231
38. Mir SS, Richter BW, Duckett CS (2000) Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96:4307-4312
39. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005) Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 84:1-12
40. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Drakos E et al. (2006) c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 107:2544-2547
41. Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111:3322-3330
42. Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106:408-418
43. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang LL, Kopinja J et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401-406
44. Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20:323-370
45. Safa AR, Day TW, Wu CH (2008) Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8:37-46
46. Schafer ZT, Kornbluth S (2006) The apoptosome: physiological, developmental, and pathological modes of regulation. Dev Cell 10:549-561
47. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF (1999) A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 94:2854-2861
48. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK (2005) Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16:1125-1138
49. Sors A, Jean-Louis F, Begue E, Parmentier L, Dubertret L, Dreano M et al. (2008) Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 14:901-911
50. Staber PB, Noehammer C, Durkop H, Schauer S, Kenner L, Linkesch W et al. (2006) mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res 30:343-348
51. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K et al. (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695
52. Uwagawa T, Li Z, Chang Z, Xia Q, Peng B, Sclabas GM et al. (2007) Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 109:2142-2153
53. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785
54. Willers J, Dummer R, Kempf W, Kundig T, Burg G, Kadin ME (2003) Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand. Clin Cancer Res 9:2744-2754
55. Wright CW, Rumble JM, Duckett CS (2007) CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 282:10252-10262
56. Yanase N, Kanetaka Y, Mizuguchi J (2007) Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and-independent manner. Oncol Rep 18:1031-1038
57. Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU et al. (2008) Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J Invest Dermatol 128:2728-2735
58. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJLM, Willemze R (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313-319